Lobbying Activity Report

1774-51413

This entry has been replaced by an amended Lobbying Activity Report: 1774-51435
Organization: Innovative Medicines Canada (Medicaments novateurs Canada)
Associated registration: 10310-1774-72
Lobbying Activity date: 2026-04-15
Arranged a meeting: Yes
Posted date: 2026-05-14

In-house lobbyists who participated in the lobbying activity: Charles Brown
Senior Public Office Holders who were lobbied in this activity: Brennan Day, MLA for Courtenay-Comox
Member(s) of the BC Legislative Assembly

Gavin Dew, MLA for Kelowna-Mission
Member(s) of the BC Legislative Assembly
 
Subject Matter of the Lobbying Activity
Specific Topics of Lobbying Communications Intended Outcomes Associated Subject Matters
Advocate for the adoption of innovative payer agreements at the pan-Canadian level incorporating real world evidence.
  • Development, establishment, amendment or termination of any program, policy, directive or guideline of the government of British Columbia or a Provincial entity
 Health
Advocate for workload capacity building and the acceleration of the work of the pan-Canadian Pharmaceutical Alliance which is an intergovernmental collaboration currently chaired by BC.
  • Development, establishment, amendment or termination of any program, policy, directive or guideline of the government of British Columbia or a Provincial entity
 Health
Advocate regarding provincial government funding decisions for British Columbia’s PharmaCare program, including budget allocations.
  • Development, establishment, amendment or termination of any program, policy, directive or guideline of the government of British Columbia or a Provincial entity
 Finances and Budgets, Health
Advocate regarding provincial policies governing the assessment, reimbursement and formulary listing of medicines in BC.
  • Development, establishment, amendment or termination of any program, policy, directive or guideline of the government of British Columbia or a Provincial entity
 Health
Engage with the BC government to improve access to innovative medicines and vaccines, and advance collaborative, data-driven procurement approaches that enhance patient outcomes, strengthen BC’s life sciences sector and promote health system sustainability.
  • Development, establishment, amendment or termination of any program, policy, directive or guideline of the government of British Columbia or a Provincial entity
 Government Procurement, Health
Policy measures to ensure security of drug supply in Canada and preserve Canada’s attractiveness for biopharmaceutical launches, including in response to foreign pricing regulations and their impact on patient access and economic growth in British Colombia
  • Development, establishment, amendment or termination of any program, policy, directive or guideline of the government of British Columbia or a Provincial entity
 Economic Development and Trade, Health, Intellectual Property, International Relations, International Trade, Science and Technology
Advocate for the adoption of innovative payer agreements at the pan-Canadian level that would incorporate real world evidence Footnote1
  • Development, establishment, amendment or termination of any program, policy, directive or guideline of the government of British Columbia or a Provincial entity
 Health Footnote1
Advocate for workload capacity building and the acceleration of the work of the pan-Canadian Pharmaceutical Alliance which is an intergovernmental collaboration currently chaired by BC Footnote1
  • Development, establishment, amendment or termination of any program, policy, directive or guideline of the government of British Columbia or a Provincial entity
 Health Footnote1
 
Lobbying Activity Report replaced on: 2026-05-14 amended entry: 1774-51435
 
Senior officer who filed this Lobbying Activity Report: Bettina Hamelin
 
The above name is that of the most senior paid officer who is responsible for filing a Lobbying Activity Report for the organization (the Designated Filer), whether that person participated in this lobbying activity or not.
 
  1. Footnote1  Indicates new information that was added through a Lobbying Activity Report.
Return to Registration for Innovative Medicines Canada (Medicaments novateurs Canada)
Date Modified: